NOKOMIS, Fla.--(BUSINESS WIRE)-- <\/p>\n
In a continuing effort to expand its research into possible cures for neurological diseases gaining in prevalence, Rainbow Coral Corp.s (RBCC) biotech subsidiary, Rainbow Biosciences, is looking to China for possible partners for stem cell research. <\/p>\n
Last month, RBCC announced that it was in talks to acquire a license to use a NASA-developed bioreactor to multiply adult stem cells for research. As RBCC closes in on an agreement with the cutting-edge devices license holders, Amarantus BioSciences (AMBS), China has emerged as a logical location to set up shop conducting medical research using the powerful tool. <\/p>\n
With a massive, growing population of senior citizens and a scientific community that is receptive to advanced stem cell research, China could be an ideal choice for RBCCs work. Seniors are at the highest risk for devastating neurological disorders such as Parkinsons and Alzheimers, and the countrys number of senior citizens will hit 437 million by 2051. <\/p>\n
Right now, all signs point to China as the obvious choice for both our company and our shareholders, said RBCC CEO Patrick Brown. The cheaper labor costs there, as well as a receptive market, make China a logical location to search for potential research partners that can utilize the bioassembler technology in a meaningful way. <\/p>\n
There is certainly no space-age technology like the bioassembler available in China today, he added. <\/p>\n
RBCC plans to pursue a license to use the bioreactor for stem cell expansion in China and other markets around the world potentially in excess of $100 billion. <\/p>\n
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ:AMGN),Cell Therapeutics, Inc. (CTIC), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY). <\/p>\n
For more information on Rainbow BioSciences, please visitwww.rainbowbiosciences.com\/investors. <\/p>\n
Follow us on Twitter atwww.twitter.com\/RBCCinfo. <\/p>\n<\/p>\n
Go here to see the original: NOKOMIS, Fla.--(BUSINESS WIRE)-- In a continuing effort to expand its research into possible cures for neurological diseases gaining in prevalence, Rainbow Coral Corp.s (RBCC) biotech subsidiary, Rainbow Biosciences, is looking to China for possible partners for stem cell research. Last month, RBCC announced that it was in talks to acquire a license to use a NASA-developed bioreactor to multiply adult stem cells for research. As RBCC closes in on an agreement with the cutting-edge devices license holders, Amarantus BioSciences (AMBS), China has emerged as a logical location to set up shop conducting medical research using the powerful tool. With a massive, growing population of senior citizens and a scientific community that is receptive to advanced stem cell research, China could be an ideal choice for RBCCs work. Seniors are at the highest risk for devastating neurological disorders such as Parkinsons and Alzheimers, and the countrys number of senior citizens will hit 437 million by 2051. Right now, all signs point to China as the obvious choice for both our company and our shareholders, said RBCC CEO Patrick Brown. The cheaper labor costs there, as well as a receptive market, make China a logical location to search for potential research partners that can utilize the bioassembler technology in a meaningful way. There is certainly no space-age technology like the bioassembler available in China today, he added. RBCC plans to pursue a license to use the bioreactor for stem cell expansion in China and other markets around the world potentially in excess of $100 billion. Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ:AMGN),Cell Therapeutics, Inc. (CTIC), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY). For more information on Rainbow BioSciences, please visitwww.rainbowbiosciences.com\/investors. Follow us on Twitter atwww.twitter.com\/RBCCinfo. Continue reading
\nRBCC Looks to China for Stem Cell Research<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"